id:"swepub:oai:DiVA.org:liu-14537"
Search: id:"swepub:oai:DiVA.org:liu-14537" > p53 polymorphic var...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Wegman (Palmebäck), PiaLinköpings universitet,Cellbiologi,Hälsouniversitetet (author)
p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients
- Article/chapterEnglish2006
Publisher, publication year, extent ...
- Ovid Technologies (Wolters Kluwer Health),2006
- printrdacarrier
Numbers
- LIBRIS-ID:oai:DiVA.org:liu-14537
- https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-14537URI
- https://doi.org/10.1097/01.fpc.0000204997.84182.69DOI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- Background: Adjuvant therapy of breast cancer patients reduces the risk of recurrence and mortality, although, a substantial proportion of patients acquire resistance and relapse in the disease. Predictors of therapeutic response are therefore important to avoid both therapy resistance and the side effects of inefficient regimes. The p53 protein is a key determinant to induce either growth arrest or apoptosis in response to cytotoxic stress. Methods: In the search for predictive markers of cancer therapy we investigated a common Arg72/Pro72 polymorphism in the p53 gene, which has been shown to influence the apoptotic potential. Using PCR and RFLP we genotyped 220 breast cancer patients randomized to radiotherapy versus chemotherapy and tamoxifen versus no tamoxifen. Results: Oestrogen-receptor positive patients possessing at least one Pro72 allele had better distant recurrence-free survival when randomized to tamoxifen compared to those who were not (P=0.0033), as also demonstrated by the significantly decreased hazard ratio (HR=0.28, 95% CI 0.12–0.65). Among patients homozygous for the Arg72 genotype the outcome was approximately equal between tamoxifen treated and non-tamoxifen treated patients (P=0.65). When the calculated hazard ratios for the genotypes were compared by an interaction test a significant difference was found (P=0.0088). Conclusion: The present report indicates that the codon 72 polymorphism in the p53 gene may be a predictor of tamoxifen response, suggesting that breast cancer patients lacking the Pro72 allele might be candidates for other therapies.
Subject headings and genre
- MEDICINE
- MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
- Stål, OlleLinköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)ollst87 (author)
- Stenmark Askmalm, MarieÖstergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Klinisk patologi och klinisk genetik(Swepub:liu)marst93 (author)
- Nordenskjöld, BoLinköpings universitet,Onkologi,Hälsouniversitetet(Swepub:liu)bono64 (author)
- Rutqvist, Lars-ErikDepartment of Oncology, Huddinge University Hospital, Stockholm, Sweden (author)
- Wingren, StenLinköpings universitet,Cellbiologi,Hälsouniversitetet(Swepub:liu)stewi96 (author)
- Linköpings universitetCellbiologi (creator_code:org_t)
Related titles
- In:Pharmacogenetics and Genomics: Ovid Technologies (Wolters Kluwer Health)16:5, s. 347-3511744-6872
Internet link
Find in a library
- Pharmacogenetics and Genomics (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Wegman (Palmebäc ...
- Stål, Olle
- Stenmark Askmalm ...
- Nordenskjöld, Bo
- Rutqvist, Lars-E ...
- Wingren, Sten
- Articles in the publication
- Pharmacogenetics ...
- By the university
- Linköping University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
